Starpharma Holdings Limited

SPL

AU000000SPL0

Pharmaceuticals

Market Closed - Australian S.E. Other stock markets 02:10:45 2024-04-26 am EDT			5-day change	1st Jan Change
0.135 ^AUD	0.00%		+3.85%	-20.59%

Apr. 08	Starpharma, Medicxi Co-Found Petalion Therapeutics; Shares Surge 16%	MT
Mar. 18	Starpharma Holdings Limited(ASX:SPL) dropped from S&P/ASX Emerging Companies Index	CI

Starpharma with Proactive at the ASX Small and Mid-Cap Conference

March 22, 2023 at 01:41 pm EDT

(via NewsDirect)

Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY) CEO Dr Jackie Fairley speaks with Proactive from the ASX Small and Mid-Cap Conference March 2023. The company is focused on the development of pharmaceutical and medical products for unmet patient needs, including in the areas of oncology and infectious diseases.

Contact Details

Proactive Investors

Jonathan Jackson

+61 413 713 744

jonathan@proactiveinvestors.com

Latest news about Starpharma Holdings Limited

Starpharma, Medicxi Co-Found Petalion Therapeutics; Shares Surge 16%	Apr. 07	MT
Starpharma Holdings Limited(ASX:SPL) dropped from S&P/ASX Emerging Companies Index	Mar. 17	CI
Starpharma Holdings Limited(ASX:SPL) dropped from S&P/ASX All Ordinaries Index	Mar. 17	CI
Starpharma Holdings Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 27	CI
Starpharma Asked to Provide More Data for US FDA Approval of Vivagel	Feb. 20	MT
Starpharma Says DEP Docetaxel Shows Positive Results from Clinical Trial	Dec. 20	MT
Starpharma Presents DEP Platform At Targeted Radiopharmaceuticals Conference in Berlin	Dec. 07	MT
Starpharma Names CEO	Nov. 09	MT
Starpharma Holdings Limited Appoints Cheryl Maley as Managing Director, Effective 8 January 2024	Nov. 09	CI
Starpharma Holdings Limited Appoints Cheryl Maley as Chief Executive Officer, Effective 8 January 2024	Nov. 09	CI
Starpharma Secures AU$7 Million Tax Rebate for Fiscal Year 2023; Shares Rise 4%	23-10-22	MT
Starpharma's Anti-Prostate Cancer Medication Shows Efficacy in Phase 2 Trials	23-10-18	MT
Starpharma Presents DEP Irinotecan Clinical Data at AACR Meeting; Shares Jump 7%	23-10-16	MT
Starpharma Completes Enrollment for COVID-19 Study	23-09-25	MT
Starpharma Holdings Limited Announces Viraleze for Respiratory and Cold Viruses	23-09-19	CI
Starpharma Holdings Limited(ASX:SPL) dropped from S&P Global BMI Index	23-09-18	CI
Starpharma Holdings Limited Announces Change of Company Secretary	23-08-27	CI
Starpharma Holdings Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-23	CI
Starpharma Radiodiagnostic Candidate Shows Imaging Benefits in Study; Shares Jump 8%	23-07-20	MT
Starpharma CEO to Retire in 2024	23-06-08	MT
Starpharma Announces Resignation of Jackie Fairley as Chief Executive Officer	23-06-08	CI
Starpharma's Viraleze Antiviral Nasal Spray Approved in Malaysia	23-06-05	MT
Starpharma CFO Starts in Role	23-04-03	MT
Starpharma Holdings Limited Appoints Justin Cahill as Company Secretary	23-04-02	CI
Starpharma Appoints CFO	23-03-03	MT

Chart Starpharma Holdings Limited

Duration

Period

More charts

Company Profile

Starpharma Holdings Limited is an Australia-based biopharmaceutical company. The principal activities of the Company consist of research, development and commercialization of dendrimer products for pharmaceutical, life-science and other applications. It is focused on developing and commercializing novel therapeutic products that address global healthcare needs. The Company is also involved in the development of nano-scale materials, including the development of VivaGel for the management and prevention of bacterial vaginosis, and as an antiviral condom coating, and VIRALEZE, an antiviral nasal spray. The Company is also applying its proprietary dendrimers to drug delivery to create improved pharmaceuticals and has developed the valuable DEP delivery platform. VIRALEZE is a broad-spectrum nasal spray intended to provide a moisturizing and protective barrier in the nose that traps and blocks cold/respiratory viruses. It also offers VivaGel BV and VivaGel Condom products.

Sector

Pharmaceuticals

Calendar

2024-08-20 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
STARPHARMA HOLDINGS LIMITED	-20.59%	36.28M
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B

Other Pharmaceuticals

Starpharma Holdings Limited

Equities

SPL

AU000000SPL0

Pharmaceuticals

Starpharma with Proactive at the ASX Small and Mid-Cap Conference

Contact Details

Latest news about Starpharma Holdings Limited

Chart Starpharma Holdings Limited

Company Profile

Income Statement Evolution

Annual profits - Rate of surprise

Sector Other Pharmaceuticals